SOPHiA GENETICS

102 articles about SOPHiA GENETICS

• Tulane University School of Medicine Uses SOPHiA GENETICS to Advance Research of Blood Cancers

  8/8/2023

  SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, announced that the Tulane University School of Medicine in New Orleans, Louisiana is live on SOPHiA GENETICS technology.

• SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023

  8/8/2023

  SOPHiA GENETICS SA today reported financial results for the second quarter ended June 30, 2023.

• SOPHiA GENETICS to Announce Financial Results for the Second Quarter of Fiscal 2023 on August 8, 2023

  7/25/2023

  SOPHiA GENETICS SA  today announced it will release its financial results for the second quarter of fiscal 2023 before U.S. markets open on Tuesday, August 8, 2023.

• Ankara Etlik City Hospital is Live on SOPHiA GENETICS Platform

  6/22/2023

  SOPHiA GENETICS announced that Ankara Etlik City Hospital, the largest hospital in the capital city of Turkey, is live on the SOPHiA DDM™ Platform.

• Institute of Oncology Ljubljana Leverages SOPHiA DDM™ Platform for Cancer Research

  5/24/2023

  SOPHiA GENETICS announced that the Institute of Oncology Ljubljana, a comprehensive public institution for detection, treatment and research of cancer, based in Ljubljana, Slovenia, is live on SOPHiA DDM™.

• Dasa Expands Its Capabilities with SOPHiA GENETICS

  5/15/2023

  SOPHiA GENETICS, a cloud-native software company and the leader in data-driven medicine, celebrates with longstanding partner, Dasa, the largest integrated healthcare network in Brazil, as it reaches a milestone of 2,000 samples analyzed for HRD status.

• SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2023

  5/9/2023

  SOPHiA GENETICS SA reported financial results for the first quarter ended March 31, 2023.

• SOPHiA GENETICS’ SOPHiA DDM™ HRD Solution is Tapped by Unipath Specialty Laboratory Limited

  5/3/2023

  SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced that Unipath Specialty Laboratory Limited, one of the leading diagnostic brands in India, is live on the SOPHiA DDM™ Homologous Recombination Deficiency Solution.

• SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2023 on May 9, 2023

  4/25/2023

  SOPHiA GENETICS  today announced it will release its financial results for the first quarter of fiscal 2023 before U.S. markets open on Tuesday, May 9, 2023.

• Tel Aviv Sourasky Medical Center Chooses SOPHiA DDMTM HRD Solution of SOPHiA GENETICS

  4/4/2023

  SOPHiA DDMTM HRD Solution will help empower clinical researchers to advance cancer research SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced that Tel Aviv Sourasky Medical Center, the largest acute care facility in Israel, has chosen to use SOPHiA DDM™ to enhance its genetic testing capabilities.

• Acutis Diagnostics Leverages SOPHiA GENETICS Technology to Create New Next Generation Sequencing Test

  3/28/2023

  SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Acutis Diagnostics, a specialized medical laboratory, will use SOPHiA DDM™ to develop a new genomic assay.

• SOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer Analysis

  3/14/2023

  SOPHiA GENETICS is partnering with Agilent to offer a comprehensive solution for cancer analysis.

• SOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation Sequencing

  3/1/2023

  SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (NYSE: QGEN) that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to enhance tumor analysis through next-generation sequencing (NGS).

• QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing

  3/1/2023

  QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM (Nasdaq: SOPH) that will bring together its QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform.

• Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution

  2/28/2023

  SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced that Synergy Oncology, part of Synergy Laboratories, a full-service diagnostic laboratory based in Mobile, Alabama, will use SOPHiA DDM™ to develop a new cancer profiling solution.

• SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full Year of Fiscal 2022 on March 7, 2023

  2/23/2023

  SOPHiA GENETICS today announced it will release its financial results for the fourth quarter and full year of fiscal 2022 before U.S. markets open on Tuesday, March 7, 2023.

• SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development

  2/13/2023

  SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a leading cloud-native global data-sharing network and health analytics platform, is partnering with AstraZeneca (LSE/STO/Nasdaq: AZN) to apply their multimodal technology and expertise to the biopharmaceutical company’s oncology portfolio.

• SOPHiA GENETICS and Leading US Cancer Center Collaborate to Combine Cancer Analysis Technology for Liquid Biopsies

  1/10/2023

  SOPHiA GENETICS™ (Nasdaq: SOPH), a cloud-native software company in the healthcare space, has entered an agreement with Memorial Sloan Kettering Cancer Center (MSK) to offer clinicians and researchers new solutions to expand their testing and analytical capabilities.

• SOPHiA GENETICS to Present at the J.P. Morgan 2023 Healthcare Conference

  1/4/2023

  SOPHiA GENETICS SA announced that Dr. Jurgi Camblong, Chief Executive Officer and Co-Founder, is scheduled to present at the J.P. Morgan 2023 Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. PST in San Francisco.

• SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2022

  11/8/2022

  SOPHiA GENETICS SA, a cloud-native software company in the healthcare space, reported financial results for the third quarter ended September 30, 2022.